Holen Sie sich die Stockscreener-App
0.2498
20.10%
0.0418
Handel nachbörslich:
.25
0.0002
+0.08%
Biorestorative Therapies Inc Aktie (BRTX) Neueste Nachrichten
Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027 - marketscreener.com
Biorestorative Therapies Says Topline Phase 2 Data For BRTX-100 Expected In Q2 2027 - TradingView
BioRestorative Therapies Completes Patient Dosing in Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease - Quiver Quantitative
Stem cell back pain shot finishes Phase 2, topline data due 2027 - Stock Titan
BRTX Should I Buy - Intellectia AI
BioRestorative Therapies (BRTX) Surges 13.66% as Stock Tests Key Resistance at $0.20Corrective Wave - Newser
What makes Biorestorative Therapies (BRTX) a new buy stock - MSN
Biorestorative Therapies, Inc. (BRTX) reports Q1 loss, misses revenue estimates - MSN
Auctus Fund (BRTX) discloses 2.7M-share, 9.9% position including warrants - Stock Titan
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
MSN Money - MSN
Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Warrants of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Options of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
BioRestorative Therapies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioRestorative Therapies, Inc. 1Q 2026: Revenue $23.2K, EPS $(0.12) — 10-Q Summary - TradingView
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioRestorative Therapies (BRTX) Q1 2026 loss, cash burn and Nasdaq bid-price risk - Stock Titan
BioRestorative presents data on stem cell-derived exosomes By Investing.com - Investing.com India
BioRestorative presents data on stem cell-derived exosomes - Investing.com UK
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals - The Manila Times
Biorestorative Therapies Presents New Preclinical Data on Source-Specific Exosome Functionality and Commercial Applications in Biocosmeceuticals - marketscreener.com
TradingKey - TradingKey
BioRestorative Therapies Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease - Orthopedics This Week
Biorestorative Therapies' BRTX-100 shows sustained pain & functional improvements in chronic lumbar disc disease - marketscreener.com
BioRestorative Therapies’ BRTX-100 Phase 2 Data Shows Continued Pain Reduction in Lumbar Disc Disease Patients - geneonline.com
BioRestorative Therapies announced that its 52-week clinical study cohort has been expanded to 25 patients. - Bitget
Back pain stem cell study shows 52% had 50% pain and function gains - Stock Titan
BRTX Stock Price, Quote & Chart | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill
BioRestorative Therapies Boosts Executive Compensation and Equity Incentives - TipRanks
Biorestorative Therapies | 8-K: Current report - Moomoo
BioRestorative Therapies awards cash bonuses to CEO Lance Alstodt, VP Francisco Silva and CFO Robert Kristal - TradingView
BioRestorative (NASDAQ: BRTX) details 2025 executive pay and bonuses - Stock Titan
Biorestorative Therapies | EFFECT: Others - Moomoo
Biorestorative Therapies | 424B3: Prospectus - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) registers 15.29M warrant shares - Stock Titan
BioRestorative to present clinical, preclinical data at ISCT - Investing.com UK
BioRestorative to present clinical, preclinical data at ISCT By Investing.com - Investing.com Nigeria
BioRestorative Therapies Presents New Data on MSC-Derived Programs at ISCT 2026 Annual Meeting - Quiver Quantitative
BioRestorative brings two programs to Dublin, including Phase 2 spine trial data - Stock Titan
Biorestorative Therapies Inc Presents New Data at ISCT 2026 Highlighting Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Biocosmeceutical Platform - marketscreener.com
Biorestorative Therapies, Inc. (BRTX) reports Q4 loss, lags revenue estimates - MSN
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform - The Manila Times
[EFFECT] BioRestorative Therapies, Inc. SEC Filing - Stock Titan
Here's why Biorestorative Therapies (BRTX) looks ripe for bottom fishing - MSN
Biorestorative Therapies | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) files S-1/A amendment; counsel opinion added - Stock Titan
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing - Yahoo! Finance Canada
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):